Personalis, Inc.
PSNLHealthcareNASDAQDiagnostics & Research
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Personalis, Inc. focuses on Diagnostics & Research services and products. Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. At a $1.69B market cap, Personalis, Inc. ranks as a small-cap company within healthcare. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample.
Market Cap
$1.69B
Beta
2.32
P/E (TTM)
—
P/E (Fwd)
-16.40
EPS (TTM)
$-1.09
EPS (Fwd)
$-0.97
ROE
-50.3%
ROA
-25.0%
Cash
$212.7M
Total Debt
$38.0M
Free CF
-$56.0M
52W Change
63.7%
Annual Financials
Cash vs Debt
Where PSNL stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, PSNL finished 34.45% above its 150-day moving average ($11.64) and 43.32% above its 200-day moving average ($10.92). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PSNL overbought or oversold?
At the October 19, 2026 close, PSNL's RSI(14) was 28.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $212.7M in cash comfortably exceeding the $38.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$56.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -50.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $65.0M (2022) to $69.6M (2025).
With a beta above 1.5, PSNL tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PSNL.